Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

103.17
+1.391.37%
Post-market: 103.170.00000.00%19:52 EDT
Volume:94.74K
Turnover:9.75M
Market Cap:4.35B
PE:-100.33
High:103.36
Open:101.87
Low:101.75
Close:101.78
52wk High:107.69
52wk Low:90.24
Shares:42.15M
Float Shares:42.15M
Volume Ratio:0.59
T/O Rate:0.22%
Dividend:1.38
Dividend Rate:1.33%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.12
PE(LYR):-100.33

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
Yesterday

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
Yesterday

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
Yesterday

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
Yesterday

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
Yesterday

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

GlobeNewswire
·
Yesterday

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Yesterday

Merck price target lowered to $163 from $166 at BofA

TIPRANKS
·
Yesterday

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Yesterday

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Yesterday

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Yesterday

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Yesterday

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Yesterday

TD Cowen Cuts Price Target on UnitedHealth Group to $402 From $430

MT Newswires Live
·
Yesterday

TD Cowen Cuts UnitedHealth PT Ahead of Q3 Results

Reuters
·
Yesterday

Wells Fargo Adjusts Price Target on Merck & Co to $165 From $170

MT Newswires Live
·
Yesterday

UnitedHealth : TD Cowen Cuts Target Price to $402 from $430

THOMSON REUTERS
·
Yesterday

Top 3 Biotech Stocks To Watch In October 2026

Simply Wall St.
·
Yesterday

RBC Capital Remains a Buy on UnitedHealth (UNH)

TIPRANKS
·
Yesterday